COVID-19 infection has protean systemic manifestations. Experience from previous
coronavirus outbreaks, including the current SARS-CoV-2, has shown an augmented risk of …

Coronavirus disease of 2019 (COVID-19) is the clinical manifestation of the respiratory
infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While …

The cardinal pathology of coronavirus disease 2019 (COVID-19) is a primary infection of
pulmonary tract cells by severe acute respiratory syndrome coronavirus 2, provoking a local …

The novel coronavirus disease (COVID-19) is associated with a high incidence of
coagulopathy and venous thromboembolism that may contribute to the worsening of the …

An ongoing global pandemic of viral pneumonia (coronavirus disease [COVID-19]), due to
the virus SARS-CoV-2, has infected millions of people and remains a threat to many more …

Abstract The 2019 coronavirus disease (COVID-19) presents with a large variety of clinical
manifestations ranging from asymptomatic carrier state to severe respiratory distress …

Abstract Background COVID-19-associated coagulopathy (CAC) characterized by the
elevated D-dimer without remarkable changes of other global coagulation markers is …

Introduction both symptomatic and asymptomatic SARS-CoV-2 infections–coined
Coronavirus disease 2019 (COVID-19)–have been linked to a higher risk of cardiovascular …

COVID-19 is widely epidemic in the world and poses a great threat to our life. Coagulopathy
is one of the major characteristics in the COVID-19 patients. A growing number of studies …

There is increasing evidence that novel coronavirus disease 2019 (COVID-19) leads to a
significant coagulopathy, a phenomenon termed “COVID-19 associated coagulopathy.” …